Основная статистика
| LEI | 5493003NRW7LS2QZRH60 |
| CIK | 883984 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ICU Medical, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 8, 2025 |
As filed with the Securities and Exchange Commission on August 8, 2025 S-8 As filed with the Securities and Exchange Commission on August 8, 2025 Registration No. |
|
| August 8, 2025 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 ICU MEDICAL INC/DE Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0. |
|
| August 7, 2025 |
AMENDED AND RESTATED OPERATING AGREEMENT OTSUKA ICU MEDICAL LLC Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the Registrant customarily and actually treats as private or confidential. |
|
| August 7, 2025 |
ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance Exhibit 99.1 ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance SAN CLEMENTE, Calif., August 7, 2025 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2025. Second Quarter 2025 Results Second quarter 2 |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Exa |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2025 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 951 Calle Amanecer San Clemente, California 92673 (Address of Principal Execut |
|
| May 30, 2025 |
Conflict Minerals Report For the Calendar Year Ended December 31, 2024 Exhibit 1.01 to Form SD Conflict Minerals Report For the Calendar Year Ended December 31, 2024 Except as otherwise indicated, all references in this report to “the Company,” “we,” “our” and “us” refer to ICU Medical, Inc. and its consolidated subsidiaries. Conflict Minerals Disclosure During the Reporting Period, the Company was engaged in the development, manufacture and sale of innovative medica |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 13, 2025 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 14, 2025 |
THIRD AMENDMENT TO THE AMENDED AND RESTATED ICU MEDICAL, INC. 2011 STOCK INCENTIVE PLAN Exhibit 10.1 THIRD AMENDMENT TO THE AMENDED AND RESTATED ICU MEDICAL, INC. 2011 STOCK INCENTIVE PLAN THIS THIRD AMENDMENT TO THE ICU MEDICAL, INC. 2011 STOCK INCENTIVE PLAN (this “Amendment”), effective as of March 28, 2025, is made and adopted by ICU Medical, Inc., a Delaware corporation (the “Company”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to t |
|
| May 8, 2025 |
ICU Medical Announces First Quarter 2025 Results Exhibit 99.1 ICU Medical Announces First Quarter 2025 Results SAN CLEMENTE, Calif., May 8, 2025 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2025. First Quarter 2025 Results First quarter 2025 revenue was $604.7 million, as compared to |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2025 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Ex |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| February 27, 2025 |
Non-Employee Director Compensation Exhibit 10.4 Non-Employee Director Compensation We currently pay our non-employee directors the following: •annual retainer of $98,500 for the Lead Director •annual retainer of $102,000 for the Chairperson of the Audit Committee •annual retainer of $92,500 for the Chairperson of the Compensation Committee •annual retainer of $85,000 for the Chairperson of the Nominating and Governance Committee Th |
|
| February 27, 2025 |
ICU Medical Announces Fourth Quarter 2024 Results and Provides Fiscal Year 2025 Guidance Exhibit 99.1 ICU Medical Announces Fourth Quarter 2024 Results and Provides Fiscal Year 2025 Guidance SAN CLEMENTE, Calif., February 27, 2025 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2024. Fourth Quarter 2024 Results Fourth quart |
|
| February 27, 2025 |
ICU Medical, Inc. (“ICU Medical”) Insider Trading Compliance Policy and Procedures Exhibit 19.1 ICU Medical, Inc. (“ICU Medical”) Insider Trading Compliance Policy and Procedures Federal and state laws prohibit trading in the Securities (as defined below) of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing this information t |
|
| February 27, 2025 |
Executive Officer Compensation Exhibit 10.3 Executive Officer Compensation The annual base salaries for our executive officers are as follows: Name Title Vivek Jain Chairman of the Board and Chief Executive Officer $ 775,000 Brian M. Bonnell Chief Financial Officer and Treasurer $ 475,000 Christian Voigtlander Chief Operating Officer $ 500,000 Daniel Woolson President $ 375,000 Virginia Sanzone Corporate Vice President, General |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2025 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-34634 ICU MEDICAL, INC. (Exact Name |
|
| February 27, 2025 |
Exhibit 21 Subsidiaries of Registrant Name State or Country of Incorporation EXC Holding Corp. |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2024 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| November 12, 2024 |
ICU Medical Announces Third Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance Exhibit 99.1 ICU Medical Announces Third Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance SAN CLEMENTE, Calif., November 12, 2024 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2024. Third Quarter 2024 Results Third quar |
|
| November 12, 2024 |
PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this “Agreement”) is entered into as of November 12, 2024, by and among OTSUKA PHARMACEUTICAL FACTORY AMERICA, INC. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. |
|
| November 8, 2024 |
ICUI / ICU Medical, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* ICU Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 44930G107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of ICU Medical, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) unde |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) 09/30/2024 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Exa |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2024 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 7, 2024 |
ICU Medical Announces Second Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance Exhibit 99.1 ICU Medical Announces Second Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance SAN CLEMENTE, Calif., August 7, 2024 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2024. Second Quarter 2024 Results Second quarter 2 |
|
| July 18, 2024 |
ICUI / ICU Medical, Inc. / SMITHS GROUP PLC - SC 13D/A Activist Investment SC 13D/A 1 ef20032530sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ICU MEDICAL, INC. (Name of Issuer) Common stock, par value $0.10 per share (Title of Class of Securities) 44930G107 (CUSIP Number) Matthew Whyte Company Secretary Smiths Group plc Level 10, 255 Blackfriars Road London, United K |
|
| May 31, 2024 |
Conflict Minerals Report For the Calendar Year Ended December 31, 2023 Exhibit 1.01 to Form SD Conflict Minerals Report For the Calendar Year Ended December 31, 2023 Except as otherwise indicated, all references in this report to “the Company,” “we,” “our” and “us” refer to ICU Medical, Inc. and its consolidated subsidiaries. Conflict Minerals Disclosure During the Reporting Period, the Company was engaged in the development, manufacture and sale of innovative medica |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 951 Calle Amanecer San Clemente, California 92673 (Address of Principal Execut |
|
| May 16, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 15, 2024 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Ex |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2024 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 7, 2024 |
ICU Medical Announces First Quarter 2024 Results Exhibit 99.1 ICU Medical Announces First Quarter 2024 Results SAN CLEMENTE, Calif., May 7, 2024 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2024. First Quarter 2024 Results First quarter 2024 revenue was $566.7 million, compared to $56 |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin |
|
| March 1, 2024 |
Power of Attorney of Smiths Group plc Exhibit 99.1 POWER OF ATTORNEY The undersigned constitutes and appoints Clare Scherrer and Matthew Whyte or any of them acting singly, as the undersigned’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the undersigned and in the undersigned’s name, place and stead, to sign any and all the Securities and Exchange Commission (the “SEC”) stateme |
|
| March 1, 2024 |
ICUI / ICU Medical, Inc. / SMITHS GROUP PLC - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ICU MEDICAL, INC. (Name of Issuer) Common Stock, par value $0.10 per share (Title of Class of Securities) 44930G107 (CUSIP Number) Matthew Whyte Company Secretary Smiths Group plc Level 10, 255 Blackfriars Road London, United Kingdom, SE1 9AX +44 (0) 20 7004 1600 (Nam |
|
| March 1, 2024 |
Power of Attorney of Smiths Group International Holdings Limited EX-99.2 3 ea0201043ex99-2icumedical.htm POWER OF ATTORNEY OF SMITHS GROUP INTERNATIONAL HOLDINGS LIMITED Exhibit 99.2 POWER OF ATTORNEY The undersigned constitutes and appoints Clare Scherrer and Matthew Whyte or any of them acting singly, as the undersigned’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the undersigned and in the undersigne |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) 02/28/2024 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 27, 2024 |
Non-Employee Director Compensation Exhibit 10.4 Non-Employee Director Compensation We currently pay our non-employee directors the following: •annual retainer of $98,500 for the Lead Director •annual retainer of $102,000 for the Chairperson of the Audit Committee •annual retainer of $92,500 for the Chairperson of the Compensation Committee •annual retainer of $85,000 for the Chairperson of the Nominating and Governance Committee Th |
|
| February 27, 2024 |
Executive Officer Compensation Exhibit 10.3 Executive Officer Compensation The annual base salaries for our executive officers are as follows: Name Title Vivek Jain Chairman of the Board and Chief Executive Officer $ 775,000 Brian M. Bonnell Chief Financial Officer and Treasurer $ 475,000 Christian Voigtlander Chief Operating Officer $ 500,000 Daniel Woolson Corporate Vice President, General Manager - Infusion Systems $ 375,000 |
|
| February 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2024 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| February 27, 2024 |
ICU MEDICAL, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED Exhibit 97.1 ICU MEDICAL, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION ICU Medical, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy This Po |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-34634 ICU MEDICAL, INC. (Exact name |
|
| February 27, 2024 |
ICU Medical Announces Fourth Quarter 2023 Results and Provides Fiscal Year 2024 Guidance Exhibit 99.1 ICU Medical Announces Fourth Quarter 2023 Results and Provides Fiscal Year 2024 Guidance SAN CLEMENTE, Calif., February 27, 2024 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended December 31, 2023. Fourth Quarter 2023 Results Fourth quarter 2023 r |
|
| February 27, 2024 |
Exhibit 21 Subsidiaries of Registrant Name State or Country of Incorporation EXC Holding Corp. |
|
| February 8, 2024 |
ICUI / ICU Medical, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* ICU Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 44930G107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| January 10, 2024 |
ICUI / ICU Medical, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0015-icumedicalinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: ICU Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 44930G107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the |
|
| December 14, 2023 |
ICU Medical, Inc. 951 Calle Amanecer San Clemente, California 92673 ICU Medical, Inc. 951 Calle Amanecer San Clemente, California 92673 December 14, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street, N.E. Washington, D.C. 20549 Attention: Michael Fay, Brian Cascio Re: ICU Medical, Inc. Form 10-K for the fiscal year ended December 31, 2022 File No. 001-34634 T |
|
| November 27, 2023 |
ICU Medical, Inc. 951 Calle Amanecer San Clemente, California 92673 ICU Medical, Inc. 951 Calle Amanecer San Clemente, California 92673 November 27, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street, N.E. Washington, D.C. 20549 Attention: Michael Fay, Brian Cascio Re: ICU Medical, Inc. Form 10-K for the fiscal year ended December 31, 2022 Form 10-Q for the qu |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 6, 2023 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. |
|
| November 6, 2023 |
ICU Medical Announces Third Quarter 2023 Results Exhibit 99.1 ICU Medical Announces Third Quarter 2023 Results SAN CLEMENTE, Calif., November 6, 2023 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended September 30, 2023. Third Quarter 2023 Results Third quarter 2023 revenue was $553.3 million, compared to $59 |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2023 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| November 3, 2023 |
AMENDED AND RESTATED BYLAWS OF ICU MEDICAL, INC. AS AMENDED AND RESTATED OCTOBER 30, 2023 ARTICLE I Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ICU MEDICAL, INC. AS AMENDED AND RESTATED OCTOBER 30, 2023 ARTICLE I Offices Section 1.1 Registered Office. The registered office shall be established and maintained with Corporation Trust Company, Corporation Trusts Center, 1209 Orange Street, City of Wilmington, County of New Castle, Delaware. The Corporation Trust Company shall be the registered agent |
|
| August 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2023 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Exa |
|
| August 7, 2023 |
ICU Medical Announces Second Quarter 2023 Results and Narrows Fiscal Year 2023 Guidance Ranges Exhibit 99.1 ICU Medical Announces Second Quarter 2023 Results and Narrows Fiscal Year 2023 Guidance Ranges SAN CLEMENTE, Calif., August 7, 2023 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Results Second quarter 2023 re |
|
| May 31, 2023 |
Conflict Minerals Report For the Calendar Year Ended December 31, 2022 Exhibit 1.01 to Form SD Conflict Minerals Report For the Calendar Year Ended December 31, 2022 Except as otherwise indicated, all references in this report to “the Company,” “we,” “our” and “us” refer to ICU Medical, Inc. and its consolidated subsidiaries. Conflict Minerals Disclosure During the Reporting Period, the Company was engaged in the development, manufacture and sale of innovative medica |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 951 Calle Amanecer San Clemente, California 92673 (Address of Principal Execut |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 17, 2023 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 22, 2023 |
SECOND AMENDMENT TO THE AMENDED AND RESTATED ICU MEDICAL, INC. 2011 STOCK INCENTIVE PLAN Exhibit 10.1 SECOND AMENDMENT TO THE AMENDED AND RESTATED ICU MEDICAL, INC. 2011 STOCK INCENTIVE PLAN THIS SECOND AMENDMENT TO THE ICU MEDICAL, INC. 2011 STOCK INCENTIVE PLAN (this “Amendment”), effective as of March 14, 2023, is made and adopted by ICU Medical, Inc., a Delaware corporation (the “Company”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to |
|
| May 9, 2023 |
Non-Employee Director Compensation EX-10.1 2 exhibit10133123.htm EX-10.1 Exhibit 10.1 Non-Employee Director Compensation We currently pay our non-employee directors the following: •annual retainer of $98,500 for the Lead Director •annual retainer of $102,000 for the Chairperson of the Audit Committee •annual retainer of $92,500 for the Chairperson of the Compensation Committee •annual retainer of $85,000 for the Chairperson of the |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Ex |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2023 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 8, 2023 |
ICU Medical Announces First Quarter 2023 Results Exhibit 99.1 ICU Medical Announces First Quarter 2023 Results SAN CLEMENTE, Calif., May 8, 2023 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended March 31, 2023. First Quarter 2023 Results First quarter 2023 revenue was $568.6 million, compared to $543.1 milli |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 15, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ICU Medical, Inc. |
|
| March 15, 2023 |
EX-99.5 Exhibit 99.5 ICU MEDICAL, INC. AMENDED AND RESTATED 2011 STOCK INCENTIVE PLAN PREFORMANCE RESTRICTED STOCK UNIT AGREEMENT 1. Issuance of Units. ICU Medical, Inc., a Delaware corporation (the “Company”), hereby issues to the Grantee (the “Grantee”) named in the Notice of Performance Restricted Stock Unit Award (the “Notice”) an award (the “Award”) of the Total Number of Performance Restrict |
|
| March 15, 2023 |
Second Amendment to ICU Medical, Inc. Amended and Restated 2011 Stock Incentive Plan EX-99.3 Exhibit 99.3 SECOND AMENDMENT TO THE AMENDED AND RESTATED ICU MEDICAL, INC. 2011 STOCK INCENTIVE PLAN THIS SECOND AMENDMENT TO THE ICU MEDICAL, INC. 2011 STOCK INCENTIVE PLAN (this “Amendment”), effective as of March 14, 2023, is made and adopted by ICU Medical, Inc., a Delaware corporation (the “Company”). Capitalized terms used but not otherwise defined herein shall have the meanings asc |
|
| March 15, 2023 |
As filed with the Securities and Exchange Commission on March 15, 2023 S-8 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No. |
|
| March 15, 2023 |
Form of Amended and Restated 2011 Stock Incentive Plan Restricted Stock Unit Award Agreement EX-99.4 Exhibit 99.4 ICU MEDICAL, INC. AMENDED AND RESTATED 2011 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT 1. Issuance of Units. ICU Medical, Inc., a Delaware corporation (the “Company”), hereby issues to the Grantee (the “Grantee”) named in the Notice of Restricted Stock Unit Award (the “Notice”) an award (the “Award”) of the Total Number of Restricted Stock Units Awarded set forth in |
|
| March 3, 2023 |
As filed with the Securities and Exchange Commission on March 3, 2023 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on March 3, 2023 Registration No. |
|
| March 3, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) ICU Medical, Inc. |
|
| February 27, 2023 |
Non-Employee Director Compensation Exhibit 10.4 Non-Employee Director Compensation We currently pay our non-employee directors the following: •annual retainer of $93,500 for the Lead Director •annual retainer of $102,000 for the Chairperson of the Audit Committee •annual retainer of $92,500 for the Chairperson of the Compensation Committee •annual retainer of $85,000 for the Chairperson of the Nominating and Governance Committee Th |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-34634 ICU MEDICAL, INC. (Exact name |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2023 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| February 27, 2023 |
Exhibit 21 Subsidiaries of Registrant Name State or Country of Incorporation EXC Holding Corp. |
|
| February 27, 2023 |
ICU Medical Announces Fourth Quarter 2022 Results and Provides Fiscal Year 2023 Guidance Exhibit 99.1 ICU Medical Announces Fourth Quarter 2022 Results and Provides Fiscal Year 2023 Guidance SAN CLEMENTE, Calif., February 27, 2023 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended December 31, 2022. Fourth Quarter 2022 Results Fourth quarter 2022 r |
|
| February 27, 2023 |
Amended and Restated ICU Medical, Inc. 2011 Stock Incentive Plan AMENDED AND RESTATED ICU MEDICAL, INC. 2011 STOCK INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. The Plan amends and restates in its entirety the ICU Medical, Inc. 2011 Stock Incentive Plan, as amen |
|
| February 27, 2023 |
Executive Officer Compensation Exhibit 10.3 Executive Officer Compensation As of March 1, 2022, the annual base salaries for our executive officers are as follows: Name Title Vivek Jain Chairman of the Board and Chief Executive Officer $ 775,000 Brian M. Bonnell Chief Financial Officer and Treasurer $ 475,000 Christian Voigtlander Chief Operating Officer $ 500,000 Daniel Woolson Corporate Vice President, General Manager - Infus |
|
| February 9, 2023 |
ICUI / ICU Medical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: ICU Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 44930G107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ R |
|
| February 6, 2023 |
ICUI / ICU Medical Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ICU Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 44930G107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 30, 2022 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| January 3, 2023 |
Second Amendment to the Executive Severance Plan EX-10.1 2 exhibit101123022.htm EX-10.1 Exhibit 10.1 Second Amendment to the Executive Severance Plan THIS SECOND AMENDMENT TO THE ICU MEDICAL, INC. EXECUTIVE SEVERANCE PLAN (this “Second Amendment”), dated as of December 30, 2022, is made and adopted by the Compensation Committee (the “Committee”) of the Board of Directors of ICU Medical, Inc., a Delaware corporation (the “Corporation”). Capitaliz |
|
| November 7, 2022 |
ICU Medical Announces Third Quarter 2022 Results The Company Reaffirms 2022 Fiscal Year Guidance Exhibit 99.1 ICU Medical Announces Third Quarter 2022 Results The Company Reaffirms 2022 Fiscal Year Guidance SAN CLEMENTE, Calif., November 7, 2022 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended September 30, 2022. Third Quarter 2022 Results Third quarter |
|
| November 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2022 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Exa |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2022 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 8, 2022 |
ICU Medical Announces Second Quarter 2022 Results Company Updated FY 2022 Guidance Exhibit 99.1 ICU Medical Announces Second Quarter 2022 Results Company Updated FY 2022 Guidance SAN CLEMENTE, Calif., August 8, 2022 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended June 30, 2022. Second Quarter 2022 Results Second quarter 2022 revenue was $5 |
|
| May 31, 2022 |
Conflict Minerals Report For the Calendar Year Ended December 31, 2021 EX-1.01 2 a2022sdexhibit101.htm EX-1.01 Exhibit 1.01 to Form SD Conflict Minerals Report For the Calendar Year Ended December 31, 2021 Except as otherwise indicated, all references in this report to “the Company,” “we,” “our” and “us” refer to ICU Medical, Inc. and its consolidated subsidiaries. Conflict Minerals Disclosure During the Reporting Period, the Company was engaged in the development, m |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 951 Calle Amanecer San Clemente, California 92673 (Address of Principal Execut |
|
| May 18, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 17, 2022 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2022 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 9, 2022 |
ICU Medical Announces First Quarter 2022 Results Exhibit 99.1 ICU Medical Announces First Quarter 2022 Results SAN CLEMENTE, Calif., May 9, 2022 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended March 31, 2022. First Quarter 2022 Results First quarter 2022 revenue was $543.1 million, compared to $318.0 milli |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Ex |
|
| April 20, 2022 |
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?) is entered into effective as of this 1st day of March, 2022 (the ?Effective Date?) by and between ICU Medical, Inc., a Delaware Corporation (the ?Company?) and Vivek Jain (?Executive?) (collectively, the ?parties?). RECITALS WHEREAS, the Company and Executive |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 15, 2022 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 21, 2022 |
Report of Independent Auditors Report of Independent Auditors To the Board of Directors of Smiths Medical 2020 Limited We have audited the accompanying consolidated financial statements of Smiths Medical 2020 Limited and its subsidiaries, which comprise the consolidated balance sheets as of 31 July 2021 and 2020, and the related consolidated income statements, consolidated comprehensive income statements, consolidated statements of changes in equity and consolidated cash flow statements for the years then ended. |
|
| March 21, 2022 |
ICU MEDICAL, INC. AND SUBSIDIARIES UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS Exhibit 99.2 ICU MEDICAL, INC. AND SUBSIDIARIES UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS On January 6, 2022 (the ?Closing Date?), ICU Medical, Inc. (the ?Company?, ?ICU Medical?, ?we? or ?us?) completed the acquisition of Smiths Medical 2020 Limited (?Smiths Medical?), the holding company of Smiths Group plc?s (?Smiths Group?) global medical device business, and its consolidated subsidiar |
|
| March 21, 2022 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 7, 2022 (January 6, 2022) ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-34634 ICU MEDICAL, INC. (Exact name |
|
| February 25, 2022 |
Executive Officer Compensation Exhibit 10.3 Executive Officer Compensation The annual base salaries for our executive officers as of January 1, 2021 are as follows: Name Title Vivek Jain Chairman of the Board and Chief Executive Officer $ 650,000 Christian Voigtlander Chief Operating Officer $ 420,000 Brian M. Bonnell Chief Financial Officer and Treasurer $ 395,000 Daniel Woolson Corporate Vice President, General Manager - Infu |
|
| February 25, 2022 |
Non-Employee Director Compensation Exhibit 10.4 Non-Employee Director Compensation We currently pay our non-employee directors the following: ?annual retainer of $93,500 for the Lead Director ?annual retainer of $97,000 for the Chairperson of the Audit Committee ?annual retainer of $87,500 for the Chairperson of the Compensation Committee ?annual retainer of $85,000 for the Chairperson of the Nominating and Governance Committee The |
|
| February 25, 2022 |
Exhibit 21 Subsidiaries of Registrant Name State or Country of Incorporation ICU Medical Sales, Inc. |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2022 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| February 24, 2022 |
ICU Medical Announces Fourth Quarter 2021 Results and Provides Fiscal Year 2022 Guidance Exhibit 99.1 ICU Medical Announces Fourth Quarter 2021 Results and Provides Fiscal Year 2022 Guidance SAN CLEMENTE, Calif., February 24, 2022 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended December 31, 2021. Fourth Quarter 2021 Results Fourth quarter 2021 r |
|
| February 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 18, 2022 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| February 10, 2022 |
ICUI / ICU Medical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01131-icumedicalinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: ICU Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 44930G107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 1, 2022 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| January 12, 2022 |
POWER OF ATTORNEY The undersigned constitutes and appoints John Shipsey and Matthew Whyte or any of them acting singly, as the undersigned?s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the undersigned and in the undersigned?s name, place and stead, to: 1. |
|
| January 12, 2022 |
ICUI / ICU Medical Inc / Smiths Group International Holdings Ltd Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* ICU MEDICAL, INC. (Name of Issuer) Common Stock, par value $0.10 per share (Title of Class of Securities) 44930G107 (CUSIP Number) Matthew Whyte Company Secretary Smiths Group plc 4th Floor, 11-12 St James?s Square London, England, SW1Y 4LB +44 (0) 20 7004 1600 (Name, A |
|
| January 12, 2022 |
Exhibit 99.1 Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the ?Act?), by and among the parties listed below, each referenced to herein as a ?Joint Filer.? The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules there |
|
| January 7, 2022 |
Exhibit 10.1 Execution Version SHAREHOLDERS AGREEMENT This Shareholders Agreement (this ?Agreement?) is dated as of January 6, 2022 between and among ICU Medical, Inc., a corporation incorporated under the laws of the State of Delaware (the ?Company?), and Smiths Group International Holdings Limited, a company incorporated in England and Wales (the ?Shareholder?). The Company and the Shareholder a |
|
| January 7, 2022 |
ICU Medical Completes the Acquisition of Smiths Medical from Smiths Group plc Exhibit 99.1 ICU Medical Completes the Acquisition of Smiths Medical from Smiths Group plc The addition of Smiths Medical syringe and ambulatory infusion devices, vascular access, and vital care products to the ICU Medical portfolio creates a leading infusion therapy company with a more robust global reach. SAN CLEMENTE, CA January 6, 2022, ICU Medical Inc. (NASDAQ: ICUI) announced that it has com |
|
| January 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 7, 2022 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 7, 2022 |
Exhibit 10.2 Execution Version CREDIT AGREEMENT Dated as of January 6, 2022 among ICU Medical, Inc., as Borrower, The Guarantors Party Hereto, The Lenders Party Hereto, and Wells Fargo Bank, National Association, as Administrative Agent, Collateral Agent, and Swingline Lender Wells Fargo Securities, LLC, Barclays Bank PLC, BofA Securities, Inc., Bank of the West, Citibank, N.A.., MUFG Bank Ltd., U |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 4, 2022 (December 31, 2021) ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2021 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| November 3, 2021 |
ICU Medical, Inc. Announces Third Quarter 2021 Results Exhibit 99.1 ICU Medical, Inc. Announces Third Quarter 2021 Results SAN CLEMENTE, Calif., November 3, 2021 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended September 30, 2021. Third Quarter 2021 Results |
|
| September 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 28, 2021 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 8, 2021 |
ICU Medical Inc. to Acquire Smiths Medical September 8, 2021 1 Exhibit 99.1 ICU Medical Inc. to Acquire Smiths Medical September 8, 2021 1 Cautionary Statements Regarding Forward-Looking Information & GAAP to Non-GAAP Financial Measures > This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are made |
|
| September 8, 2021 |
Exhibit 2.1 STRICTLY PRIVATE & CONFIDENTIAL Dated 2021 Share Sale and Purchase Agreement relating to Smiths Medical 2020 Limited between Smiths Group International Holdings Limited as Seller and ICU Medical, Inc. as Purchaser White & Case LLP 5 Old Broad Street London EC2N 1DW This Agreement is made on 2021 Between: (1) Smiths Group International Holdings Limited, a company incorporated in England |
|
| September 8, 2021 |
EXECUTION VERSION Exhibit 2.2 STRICTLY PRIVATE & CONFIDENTIAL From: ICU Medical, Inc. (the ?Purchaser?) 951 Calle Amanecer, San Clemente, CA 92673, the United States of America To: Smiths Group International Holdings Limited (the ?Seller?) c/o Smiths Group plc 4th Floor, 11-12 St James?s Square, London, England, SW1Y 4LB STRICTLY PRIVATE AND CONFIDENTIAL September 2021 Dear Sir or Madam, Project S |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 8, 2021 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| September 8, 2021 |
Exhibit 99.2 ICU Medical, Inc. to acquire Smiths Medical division from Smiths Group plc for $2.35 billion in cash and stock plus the assumption of certain liabilities and a stock price performance-based earn-out The addition of Smiths Medical syringe and ambulatory infusion devices, vascular access, and vital care products into ICU Medical creates a leading infusion therapy company with a stronger |
|
| September 8, 2021 |
Execution Version Exhibit 10.1 Wells Fargo Bank, National Association Wells Fargo Securities, LLC 550 South Tryon Street, 6th Floor Charlotte, North Carolina 28202 Barclays 745 Seventh Avenue New York, New York 10019 CONFIDENTIAL September 7, 2021 ICU Medical, Inc. 951 Calle Amanecer San Clemente, CA 92673 Attention: Brian Bonnell Re: Project Spark Commitment Letter $2,000.0 Million Senior Credit |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2021 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 4, 2021 |
ICU Medical, Inc. Announces Second Quarter 2021 Results Company Updated FY 2021 Guidance Exhibit 99.1 ICU Medical, Inc. Announces Second Quarter 2021 Results Company Updated FY 2021 Guidance SAN CLEMENTE, Calif., August 4, 2021 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended June 30, 2021. |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2021 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Exa |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 1, 2021 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 951 Calle Amanecer San Clemente, California 92673 (Address of Principal Execut |
|
| May 26, 2021 |
Conflict Minerals Report For the Calendar Year Ended December 31, 2020 Exhibit 1.01 to Form SD Conflict Minerals Report For the Calendar Year Ended December 31, 2020 Except as otherwise indicated, all references in this report to ?the Company,? ?we,? ?our? and ?us? refer to ICU Medical, Inc. and its consolidated subsidiaries. Conflict Minerals Disclosure The Company develops, manufactures and sells innovative medical products used in infusion therapy and critical car |
|
| May 14, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2021 (May 11, 2021) ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commi |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Ex |
|
| May 6, 2021 |
ICU Medical, Inc. Announces First Quarter 2021 Results Exhibit 99.1 ICU Medical, Inc. Announces First Quarter 2021 Results SAN CLEMENTE, Calif., May 6, 2021 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended March 31, 2021. First Quarter 2021 Results First qua |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2021 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 26, 2021 |
Exhibit 21 Subsidiaries of Registrant Name State or Country of Incorporation ICU Medical Sales, Inc. |
|
| February 26, 2021 |
Non-Employee Director Compensation Exhibit 10.6 Non-Employee Director Compensation We currently pay our non-employee directors the following: ?annual retainer of $93,500 for the Lead Director ?annual retainer of $97,000 for the Chairperson of the Audit Committee ?annual retainer of $87,500 for the Chairperson of the Compensation Committee ?annual retainer of $85,000 for the Chairperson of the Nominating and Governance Committee The |
|
| February 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-34634 ICU MEDICAL, INC. (Exact name |
|
| February 26, 2021 |
Executive Officer Compensation Exhibit 10.5 Executive Officer Compensation The annual base salaries for our executive officers as of January 1, 2020 are as follows: Name Title Vivek Jain Chairman of the Board and Chief Executive Officer $ 650,000 Christian Voigtlander Chief Operating Officer $ 420,000 Brian M. Bonnell Chief Financial Officer and Treasurer $ 395,000 Scott E. Lamb* Former Chief Financial Officer and Treasurer $ 3 |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 25, 2021 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| February 25, 2021 |
ICU Medical, Inc. Announces Fourth Quarter 2020 Results and Provides Fiscal Year 2021 Guidance Exhibit 99.1 ICU Medical, Inc. Announces Fourth Quarter 2020 Results and Provides Fiscal Year 2021 Guidance SAN CLEMENTE, Calif., February 25, 2021 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended Decemb |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: ICU Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 44930G107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru |
|
| November 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. |
|
| November 5, 2020 |
ICU Medical, Inc. Announces Third Quarter 2020 Results and Updates Fiscal Year 2020 Guidance Exhibit 99.1 ICU Medical, Inc. Announces Third Quarter 2020 Results and Updates Fiscal Year 2020 Guidance SAN CLEMENTE, Calif., November 5, 2020 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended September |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 5, 2020 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| August 10, 2020 |
ICU Medical, Inc. Announces Second Quarter 2020 Results Exhibit 99.1 ICU Medical, Inc. Announces Second Quarter 2020 Results SAN CLEMENTE, Calif., August 10, 2020 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended June 30, 2020. Second Quarter 2020 Results Seco |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Exa |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2020 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 951 Calle Amanecer San Clemente, California 92673 (Address of Principal Execut |
|
| June 1, 2020 |
Conflict Minerals Report For the Calendar Year Ended December 31, 2019 Exhibit 1.01 to Form SD Conflict Minerals Report For the Calendar Year Ended December 31, 2019 Except as otherwise indicated, all references in this report to “the Company,” “we,” “our” and “us” refer to ICU Medical, Inc. and its consolidated subsidiaries. Conflict Minerals Disclosure The Company develops, manufactures and sells innovative medical products used in infusion therapy and critical car |
|
| May 15, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2020 (May 13,2020) ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commis |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Ex |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2020 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 7, 2020 |
ICU Medical, Inc. Announces First Quarter 2020 Results and Updates Fiscal Year 2020 Guidance Exhibit 99.1 ICU Medical, Inc. Announces First Quarter 2020 Results and Updates Fiscal Year 2020 Guidance SAN CLEMENTE, Calif., May 7, 2020 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended March 31, 2020 |
|
| April 3, 2020 |
ICUI / ICU Medical, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin |
|
| March 2, 2020 |
Non-Employee Director Compensation Exhibit 10.6 Non-Employee Director Compensation We currently pay our non-employee directors the following: •annual retainer of $93,500 for the Lead Director •annual retainer of $97,000 for the Chairperson of the Audit Committee •annual retainer of $87,500 for the Chairperson of the Compensation Committee •annual retainer of $85,000 for the Chairperson of the Nominating and Governance Committee The |
|
| March 2, 2020 |
Exhibit 21 Subsidiaries of Registrant Name State or Country of Incorporation ICU Medical Sales, Inc. |
|
| March 2, 2020 |
Executive Officer Compensation Exhibit 10.5 Executive Officer Compensation The annual base salaries for our executive officers as of January 1, 2019 are as follows: Name Title Vivek Jain Chairman of the Board and Chief Executive Officer $ 650,000 Christian Voigtlander Chief Operating Officer $ 420,000 Scott E. Lamb Chief Financial Officer $ 395,150 Daniel Woolson Corporate Vice President, General Manager - Infusion Systems $ 30 |
|
| March 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-34634 ICU MEDICAL, INC. (Exact name |
|
| March 2, 2020 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURUSANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 AS of March 2, 2020, ICU Medical, Inc. (“we,” “our,” “us,” or the “Company”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following summary of the terms of our common stock is based upon |
|
| March 2, 2020 |
First Amendment to ICU Medical, Inc. Amended and Restated 2011 Stock Incentive Plan Exhibit 10.12 FIRST AMENDMENT TO ICU MEDICAL, INC. AMENDED AND RESTATED 2011 STOCK INCENTIVE PLAN THIS FIRST AMENDMENT TO THE ICU MEDICAL, INC. AMENDED AND RESTATED 2011 STOCK INCENTIVE PLAN (this “First Amendment”), dated as of December 31, 2019, is made and adopted by the Board of Directors (the “Board”) of ICU Medical, Inc., a Delaware corporation (the “Corporation”). Capitalized terms used but |
|
| February 28, 2020 |
Exhibit 10.1 February 27, 2020 Scott Lamb Subject: Retirement & Separation Agreement Dear Scott, As discussed and mutually agreed, your employment with ICU Medical, Inc. (the “Company”) will end on 4/3/20 (the “Separation Date”). On your Separation Date, you shall be entitled to terms summarized in this letter (this “Agreement”) upon satisfaction of the obligations set forth in this Agreement and |
|
| February 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2020 (February 27,2020) ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporatio |
|
| February 27, 2020 |
ICU Medical, Inc. Announces Fourth Quarter 2019 Results Exhibit 99.1 ICU Medical, Inc. Announces Fourth Quarter 2019 Results SAN CLEMENTE, Calif., February 27, 2020 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended December 31, 2019. Fourth Quarter 2019 Result |
|
| February 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2020 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| February 12, 2020 |
ICUI / ICU Medical, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: ICU Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 44930G107 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rul |
|
| January 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 31, 2019 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| January 6, 2020 |
FIRST AMENDMENT TO ICU MEDICAL, INC. EXECUTIVE SEVERANCE PLAN FIRST AMENDMENT TO ICU MEDICAL, INC. EXECUTIVE SEVERANCE PLAN THIS FIRST AMENDMENT TO THE ICU MEDICAL, INC. EXECUTIVE SEVERANCE PLAN (this “First Amendment”), dated as of December 31, 2019, is made and adopted by the Compensation Committee (the “Committee”) of the Board of Directors of ICU Medical, Inc., a Delaware corporation (the “Corporation”). Capitalized terms used but not otherwise defined h |
|
| November 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2019 (November 11, 2019) ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporati |
|
| November 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. |
|
| November 12, 2019 |
ICU Medical, Inc. Announces Third Quarter 2019 Results Exhibit 99.1 ICU Medical, Inc. Announces Third Quarter 2019 Results SAN CLEMENTE, Calif., November 11, 2019 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended September 30, 2019. Third Quarter 2019 Results |
|
| November 12, 2019 |
ICU Medical, Inc (ICUI) CEO Vivek Jain on Q3 2019 Results - Earnings Call Transcript Exhibit 99.2 ICU Medical, Inc (ICUI) CEO Vivek Jain on Q3 2019 Results - Earnings Call Transcript Nov. 11, 2019 8:48 PM ET | About: ICU Medical, Inc. (ICUI) ICU Medical, Inc (NASDAQ:ICUI) Q3 2019 Earnings Conference Call November 11, 2019 4:30 PM ET Company Participants John Mills - Partner, ICR, Inc Vivek Jain - Chairman and Chief Executive Officer Scott Lamb - Chief Financial Officer and Treasur |
|
| August 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Exa |
|
| August 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2019 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 7, 2019 |
ICU Medical, Inc. Announces Second Quarter 2019 Results Company Updates FY 2019 Guidance Exhibit 99.1 ICU Medical, Inc. Announces Second Quarter 2019 Results Company Updates FY 2019 Guidance SAN CLEMENTE, Calif., August 7, 2019 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended June 30, 2019. |
|
| July 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 8, 2019 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 8, 2019 |
ICU Medical CFO Announces Intention to Retire from CFO Role After Close of FY19 Exhibit 99.1 ICU Medical CFO Announces Intention to Retire from CFO Role After Close of FY19 SAN CLEMENTE, Calif., July 8, 2019 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care applications, today announced that Scott E. Lamb, its Chief Financial Officer and Treasurer, has |
|
| May 31, 2019 |
ICUI / ICU Medical, Inc. SD - - SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 951 Calle Amanecer San Clemente, California 92673 (Address of Principal Execut |
|
| May 31, 2019 |
Conflict Minerals Report For the Calendar Year Ended December 31, 2018 Exhibit 1.01 to Form SD Conflict Minerals Report For the Calendar Year Ended December 31, 2018 Except as otherwise indicated, all references in this report to “the Company,” “we,” “our” and “us” refer to ICU Medical, Inc. and its consolidated subsidiaries. Conflict Minerals Disclosure The Company develops, manufactures and sells innovative medical products used in infusion therapy and critical car |
|
| May 16, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 15, 2019 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 10, 2019 |
Exhibit 10.1 April 1, 2019 Alison Burcar Subject: Confidential Agreement Dear Alison, This letter outlines our mutual agreement in connection with terms and conditions of your employment with ICU Medical. Effective April 1, 2019, you shall retain responsibility for R&D and Product Development Process Efficiency within IV Consumables as Corporate Vice President, Product Development/R&D. You will co |
|
| May 10, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2019 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Ex |
|
| May 9, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2019 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 9, 2019 |
ICU Medical, Inc. Announces First Quarter 2019 Results Exhibit 99.1 ICU Medical, Inc. Announces First Quarter 2019 Results SAN CLEMENTE, Calif., May 9, 2019 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended March 31, 2019. First Quarter 2019 Results First qua |
|
| May 6, 2019 |
ICUI / ICU Medical, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat |
|
| April 5, 2019 |
ICUI / ICU Medical, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin |
|
| April 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 1, 2019 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE (State or other jurisdiction of incorporation) 001-34634 33-0022692 (Commission File Num |
|
| March 4, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2019 ICU MEDICAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-19974 33-0022692 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 1, 2019 |
Executive Officer Compensation Exhibit 10.7 Executive Officer Compensation The annual base salaries for our executive officers as of January 1, 2019 are as follows: Name Title Vivek Jain Chairman of the Board and Chief Executive Officer $ 650,000 Christian Voigtlander Chief Operating Officer $ 420,000 Scott E. Lamb Chief Financial Officer $ 395,150 Alison D. Burcar Corporate Vice President, Product Strategy IV Consumables $ 315 |
|
| March 1, 2019 |
ICUI / ICU Medical, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-34634 ICU MEDICAL, INC. (Exact name |
|
| March 1, 2019 |
Non-Employee Director Compensation Exhibit 10.8 Non-Employee Director Compensation We currently pay our non-employee directors the following: •annual retainer of $93,500 for the Lead Director •annual retainer of $97,000 for the Chairperson of the Audit Committee •annual retainer of $87,500 for the Chairperson of the Compensation Committee •annual retainer of $85,000 for the Chairperson of the Nominating and Governance Committee The |
|
| March 1, 2019 |
EX-21 4 exhibit21subsidiariesofreg.htm EXHIBIT 21 SUBSIDIARIES OF REGISTRANT Exhibit 21 Subsidiaries of Registrant Name State or Country of Incorporation ICU Medical Sales, Inc. Delaware ICU Medical de Mexico, S. de R. L. de C.V. Mexico ICU Medical Europe S.r.l. Italy ICU World, Inc. Delaware ICU Medical Germany GmbH Germany ICU Medical Slovakia S.r.o. Slovak Republic ICU Medical, LLC California M |
|
| February 28, 2019 |
ICU Medical, Inc. Announces Fourth Quarter 2018 Results Exhibit 99.1 ICU Medical, Inc. Announces Fourth Quarter 2018 Results SAN CLEMENTE, Calif., February 28, 2019 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care applications, today announced financial results for the quarter ended December 31, 2018. Fourth Quarter 2018 Results |
|
| February 28, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2019 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| February 12, 2019 |
ICUI / ICU Medical, Inc. / VANGUARD GROUP INC Passive Investment icumedicalinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6 )* Name of issuer: ICU Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 44930G107 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate box to des |
|
| November 16, 2018 |
ICUI / ICU Medical, Inc. / PFIZER INC - SCHEDULE 13D AMENDMENT 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ICU Medical, Inc. (Name of Issuer) Common Stock, $0.10 par value per share (Title of Class of Securities) 44930G107 (CUSIP Number) Margaret M. Madden, Esq. Vice President and Corporate Secretary, Chief Governance Counsel Pfizer Inc. 235 East 42nd Street |
|
| November 15, 2018 |
ICUI / ICU Medical, Inc. S-3ASR S-3ASR Table of Contents As filed with the Securities and Exchange Commission on November 15, 2018 Registration No. |
|
| November 15, 2018 |
Specimen of Common Stock Certificate. EX-4.1 Exhibit 4.1 ICU Medical, Inc. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SEE REVERSE FOR FOR CERTAIN DEFINITIONS This Certifies that CUSIP 449306 10 7 is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, PAR VALUE $.10 PER SHARE, OF ICU MEDICAL, INC. transferable on the books of the Corporation by the holder hereof in person or by duly authorized Attorney u |
|
| November 15, 2018 |
EX-4.3 4 d650405dex43.htm EX-4.3 Exhibit 4.3 STOCK PURCHASE AND SALE AGREEMENT THIS STOCK PURCHASE AND SALE AGREEMENT (“Agreement”) is made as of November 13, 2018, by and among the purchasers listed on Exhibit A and B attached hereto (each, a “Buyer” and collectively, the “Buyers”), C.P. Pharmaceuticals International C.V., a commanditaire vennootschap organized under the laws of the Netherlands ( |
|
| November 15, 2018 |
EX-4.2 Exhibit 4.2 STOCK PURCHASE AND SALE AGREEMENT THIS STOCK PURCHASE AND SALE AGREEMENT (“Agreement”) is made as of November 13, 2018, by and among the purchasers listed on Exhibit A attached hereto (each, a “Buyer” and collectively, the “Buyers”), C.P. Pharmaceuticals International C.V., a commanditaire vennootschap organized under the laws of the Netherlands (“Seller”), and ICU Medical, Inc. |
|
| November 15, 2018 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2018 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission |
|
| November 15, 2018 |
ICU MEDICAL, INC. AND SUBSIDIARIES UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION EX-99.2 Exhibit 99.2 ICU MEDICAL, INC. AND SUBSIDIARIES UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION On February 3, 2017 (the “Closing Date”), ICU Medical, Inc. (the “Company”, “ICU”, “we” or “us”) completed the acquisition of Pfizer Inc’s (“Pfizer”) Hospira Infusion Systems (“HIS”) business (the “Acquisition”) pursuant to the terms and conditions of the Amended and Restated Stock and Asset |
|
| November 15, 2018 |
EX-99.1 Exhibit 99.1 Pfizer Infusion Systems (A Business Unit of Pfizer Inc.) Combined Statements of Income (Loss) and Comprehensive Income (Loss), Business Unit Equity, and Cash Flows for the years ended December 31, 2016 and 2015 with Independent Auditors’ Report Thereon 1 Pfizer Infusion Systems (A Business Unit of Pfizer Inc.) Table of Contents Pages INDEPENDENT AUDITORS’ REPORT 3 COMBINED FIN |
|
| November 9, 2018 |
ICUI / ICU Medical, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2018 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. |
|
| November 8, 2018 |
Exhibit 99.1 ICU Medical, Inc. Announces Third Quarter 2018 Results Company Modifies FY 2018 Guidance and Provides Initial FY 2019 Adjusted EBITDA Guidance SAN CLEMENTE, Calif., November 8, 2018 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced |
|
| November 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 8, 2018 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File |
|
| August 15, 2018 |
ICUI / ICU Medical, Inc. / PFIZER INC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ICU Medical, Inc. (Name of Issuer) Common Stock, $0.10 par value per share (Title of Class of Securities) 44930G107 (CUSIP Number) Margaret M. Madden, Esq. Vice President and Corporate Secretary, Chief Governance Counsel Pfizer Inc. 235 East 42nd Street |
|
| August 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 9, 2018 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 9, 2018 |
ICU Medical, Inc. Announces Second Quarter 2018 Results Company Updates FY 2018 Guidance Exhibit 99.1 ICU Medical, Inc. Announces Second Quarter 2018 Results Company Updates FY 2018 Guidance SAN CLEMENTE, Calif., August 9, 2018 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended June 30, 2018. |
|
| August 9, 2018 |
ICUI / ICU Medical, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2018 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Exa |
|
| May 31, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 951 Calle Amanecer San Clemente, California 92673 (Address of Principal Execut |
|
| May 31, 2018 |
Conflict Minerals Report For the Calendar Year Ended December 31, 2017 Exhibit 1.01 to the Form SD Conflict Minerals Report For the Calendar Year Ended December 31, 2017 Except as otherwise indicated, all references in this report to “the Company,” “we,” “our” and “us” refer to ICU Medical, Inc. and its consolidated subsidiaries. Conflict Minerals Disclosure Conflict Minerals Disclosure The Company develops, manufactures and sells innovative medical devices used in v |
|
| May 17, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 15, 2018 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 10, 2018 |
ICUI / ICU Medical, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2018 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Ex |
|
| May 10, 2018 |
AMENDED AND RESTATED ICU MEDICAL, INC. 2011 STOCK INCENTIVE PLAN Exhibit 10.1 AMENDED AND RESTATED ICU MEDICAL, INC. 2011 STOCK INCENTIVE PLAN 1.Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. The Plan amends and restates in its entirety the ICU Medical, Inc. 2011 Stock Incentive P |
|
| May 9, 2018 |
ICU Medical, Inc. Announces First Quarter 2018 Results Exhibit 99.1 ICU Medical, Inc. Announces First Quarter 2018 Results SAN CLEMENTE, Calif., May 9, 2018 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care applications, today announced financial results for the quarter ended March 31, 2018. First Quarter 2018 Results First quar |
|
| May 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2018 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 5, 2018 |
ICUI / ICU Medical, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin |
|
| March 16, 2018 |
Executive Officer Compensation Exhibit 10.14 Executive Officer Compensation The annual base salaries for our executive officers as of January 1, 2018 are as follows: Name Title Vivek Jain Chairman of the Board and Chief Executive Officer $ 650,000 Scott E. Lamb Chief Financial Officer $ 395,150 Steven C. Riggs Vice President of Operations $ 360,582 Alison D. Burcar Vice President and General Manager of Infusion Systems $ 315,00 |
|
| March 16, 2018 |
Non-Employee Director Compensation Exhibit 10.15 Non-Employee Director Compensation We currently pay our non-employee directors the following: •annual retainer of $93,500 for the Lead Director •annual retainer of $97,000 for the Chairperson of the Audit Committee •annual retainer of $87,500 for the Chairperson of the Compensation Committee •annual retainer of $85,000 for the Chairperson of the Nominating and Governance Committee Th |
|
| March 16, 2018 |
ICUI / ICU Medical, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-34634 ICU MEDICAL, INC. (Exact name |
|
| March 16, 2018 |
EX-21 4 exhibit21subsidiariesofreg.htm EXHIBIT 21 Exhibit 21 Subsidiaries of Registrant Name State or Country of Incorporation ICU Medical Sales, Inc. Delaware ICU Medical de Mexico, S. de R. L. de C.V. Mexico ICU Medical Europe S.r.l. Italy ICU World, Inc. Delaware ICU Medical Germany GmbH Germany ICU Medical Slovakia S.r.o. Slovak Republic ICU Medical, LLC California Medical Connections C.V. Net |
|
| March 2, 2018 |
ICUI / ICU Medical, Inc. NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2017 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report o |
|
| March 1, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 1, 2018 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 1, 2018 |
Exhibit 99.1 ICU Medical, Inc. Announces Fourth Quarter and Fiscal Year 2017 Results Company Updates FY 2018 Adjusted EPS Guidance SAN CLEMENTE, Calif., March 1, 2018 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care applications, today announced financial results for the qu |
|
| February 27, 2018 |
ICUI / ICU Medical, Inc. 8-A12B/A Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 33-0022692 (State or other jurisdiction of incorporation) (IRS Employer Identification |
|
| February 9, 2018 |
ICUI / ICU Medical, Inc. / VANGUARD GROUP INC Passive Investment icumedicalinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5 )* Name of issuer: ICU Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 44930G107 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropriate box to des |
|
| January 5, 2018 |
POWER OF ATTORNEY Know all by these presents that the undersigned hereby constitutes and appoints each of Paula Darbyshire, Michelle Lebednik and Alejandro Parras, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of ICU Medical, Inc. |
|
| January 5, 2018 |
POWER OF ATTORNEY Know all by these presents that the undersigned hereby constitutes and appoints each of Paula Darbyshire, Michelle Lebednik and Alejandro Parras, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of ICU Medical, Inc. |
|
| January 5, 2018 |
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 4, 2018 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commissi |
|
| November 9, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 9, 2017 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commiss |
|
| November 9, 2017 |
Exhibit Exhibit 99.1 ICU Medical, Inc. Announces Third Quarter 2017 Results Company Updates FY 2017 Guidance and Provides Initial FY 2018 EBITDA and Adjusted EPS Guidance SAN CLEMENTE, Calif., November 9, 2017 (GLOBE NEWSWIRE) - ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care applications, t |
|
| November 9, 2017 |
ICUI / ICU Medical, Inc. ICUI 09.30.2017 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2017 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. |
|
| November 9, 2017 |
Execution Version Revolving Credit CUSIP Number: 44931YAB3 $150,000,000 REVOLVING CREDIT AGREEMENT dated as of November 8, 2017, by and among ICU MEDICAL, INC. |
|
| September 5, 2017 |
Document ICU Medical, Inc. September 5, 2017 VIA EDGAR Brian Cascio Accounting Branch Chief Office of Electronics and Machinery Division of Corporation Finance United States Securities and Exchange Commission Mail Stop 3030 100 F Street, N.E. Washington, D.C. 20549 Re: ICU Medical Inc. Form 10-K for the Fiscal Year Ended December 31, 2016 Filed March 1, 2017 Form 10-Q for the Quarterly Period Ende |
